胶原角膜透镜植入术用于屈光矫正临床转化研究

注册号:

Registration number:

ChiCTR2200059873 

最近更新日期:

Date of Last Refreshed on:

2023-03-13 12:39:51 

注册时间:

Date of Registration:

2022-05-13 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

胶原角膜透镜植入术用于屈光矫正临床转化研究

Public title:

Clinical translational study of corneal collagen lens implantation for refractive correction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

胶原角膜透镜植入术用于屈光矫正临床转化研究

Scientific title:

Clinical translational study of corneal collagen lens implantation for refractive correction

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙远 

研究负责人:

沈晔 

Applicant:

Sun Yuan 

Study leader:

Shen Ye 

申请注册联系人电话:

Applicant telephone:

+86 18258453879

研究负责人电话:

Study leader's
telephone:

+86 13605711083

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

drsunyuan@163.com

研究负责人电子邮件:

Study leader's E-mail:

idrshen@zju.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市上城区庆春路79号

研究负责人通讯地址:

浙江省杭州市上城区庆春路79号

Applicant address:

79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang

Study leader's address:

79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学医学院附属第一医院

Applicant's institution:

The First Affiliated Hospital, College of Medicine, Zhejiang University

研究负责人所在单位:

浙江大学医学院附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital, College of Medicine, Zhejiang University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

浙大一院伦审2022研第024号-会

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属第一医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of The First Affiliated Hospital, College of Medicine, Zhejiang University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-03-28 00:00:00

伦理委员会联系人:

厉有名

Contact Name of the ethic committee:

Li Youming

伦理委员会联系地址:

浙江省杭州市上城区庆春路79号

Contact Address of the ethic committee:

79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属第一医院

Primary sponsor:

The First Affiliated Hospital, College of Medicine, Zhejiang University

研究实施负责(组长)单位地址:

浙江省杭州市上城区庆春路79号

Primary sponsor's address:

79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

徐汇

Country:

China

Province:

Shanghai

City:

Xuhui

单位(医院):

复旦大学附属眼耳鼻喉科医院

具体地址:

上海市徐汇区汾阳路83号

Institution
hospital:

Eye and ENT Hospital of Fudan University

Address:

83 Fenyang Road, Xuhui district, Shanghai

国家:

中国

省(直辖市):

北京

市(区县):

东城

Country:

China

Province:

Beijing

City:

Dongcheng

单位(医院):

北京协和医院

具体地址:

北京市东城区帅府园1号

Institution
hospital:

Peking Union Medical College Hospital

Address:

1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

四川省成都市国学巷37号

Institution
hospital:

West China Hospital of Sichuan University

Address:

37 Guoxue Alley, Wuhou District, Chengdu, Sichuan

国家:

中国

省(直辖市):

湖北

市(区县):

武汉

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属同济医院

具体地址:

湖北省武汉市解放大道1095号

Institution
hospital:

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Address:

1095 Jiefang Avenue, Wuhan, Hubei

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejjiang

City:

Hangzhou

单位(医院):

浙江大学医学院附属第一医院

具体地址:

浙江省杭州市上城区庆春路79号

Institution
hospital:

The First Affiliated Hospital, College of Medicine, Zhejiang University

Address:

79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang

经费或物资来源:

中国科学院“ 器官重建与制造”战略性先导科技专项, No.XDA16040200

Source(s) of funding:

The Strategic Priority Research Program of Chinese Academy of Sciences, Grant No.XDA16040200

研究疾病:

屈光不正  

Target disease:

refractive error

研究疾病代码:

Target disease code:

研究类型:

治疗研究

Study type:

Treatment study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

单臂 

Study design:

Single arm 

研究目的:

本研究旨在探索一种全新的角膜屈光手术方式,将特定屈光度的胶原角膜透镜置于角膜内,重构角膜屈光系统,矫正近视、远视及散光,此种手术方式完全避免了目前主流的角膜激光手术需切削角膜导致的相关并发症。本研究拟通过临床试验验证手术的有效性、安全性、可逆性,术后视觉质量以及长期并发症,为广泛开展临床治疗提供理论依据。  

Objectives of Study:

This study aims to explore a new method of corneal refractive surgery, in which a specific refractive lens of collagen cornea is placed in the cornea to reconstruct the corneal refractive system and correct myopia, hyperopia and astigmatism. This surgical method completely avoids the corneal complications caused by cutting in the current mainstream laser corneal surgery. This study intends to verisfy the effectiveness, safety, reversibility, postoperative visual quality and long-term complications of surgery through clinical trials, so as to provide theoretical basis for extensive clinical treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 存在角膜疾患;
2. 合并青光眼,眼底病变、严重干眼症的患者;
3. 有严重系统性疾病。

Exclusion criteria:

1. Patients with corneal disorders;
2. Patients with glaucoma, fundus lesions, and severe dry eye disease;
3. Patients with serious systemic diseases.

研究实施时间:

Study execute time:

From 2022-06-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-05-01 00:00:00 To 2024-06-01 00:00:00

干预措施:

Interventions:

组别:

实验组

样本量:

50

Group:

Experiment group

Sample size:

干预措施:

植入角膜胶原透镜

干预措施代码:

Intervention:

Corneal collagen lens implantation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学医学院附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital, College of Medicine, Zhejiang University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

徐汇 

Country:

China

Province:

Shanghai

City:

Xuhui

单位(医院):

复旦大学附属眼耳鼻喉科医院 

单位级别:

三甲 

Institution
hospital:

Eye and ENT Hospital of Fudan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

东城 

Country:

China

Province:

Beijing

City:

Dongcheng

单位(医院):

北京协和医院 

单位级别:

三甲 

Institution
hospital:

Peking Union Medical College Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属同济医院 

单位级别:

三甲 

Institution
hospital:

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

裸眼视力

指标类型:

主要指标

Outcome:

Corrected visual acuity, UCVA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

屈光度

指标类型:

次要指标

Outcome:

Diopter

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

最佳矫正视力

指标类型:

次要指标

Outcome:

Best Corrected Visual Acuity, BCVA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

像差

指标类型:

次要指标

Outcome:

Aberration

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应发生率

指标类型:

次要指标

Outcome:

Incidence of adverse reactions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机试验

Randomization Procedure (please state who generates the random number sequence and by what method):

not randomiazation procedure

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

standard data collection

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-05-13 14:48:37